Tocilizumab for the treatment of steroid refractory graft-versus-host disease

William R. Drobyski, Marcelo Pasquini, Kathy Kovatovic, Jeanne Palmer, J. Douglas Rizzo, Ayman Saad, Wael Saber, Parameswaran Hari

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Corticosteroid refractory graft-versus-host disease (GVHD) is one of the major challenges in the management of allogeneic stem cell transplant recipients. Although numerous agents have been employed to treat this patient population, no standardized second-line therapy exists. In this study, we report our experience with the administration of tocilizumab, an anti-interleukin 6 receptor antibody, in the treatment of steroid refractory GVHD. Tocilizumab was administered to 8 patients with refractory acute (n = 6) or chronic GVHD (cGVHD) (n = 2) once every 3 to 4 weeks. The majority of patients with acute GVHD (aGVHD) had grade IV organ involvement of the skin or gastrointestinal tract, whereas both patients with cGVHD had long-standing severe skin sclerosis at the time of treatment. There were no allergic or infusion-related adverse events. Treatment was discontinued in one patient over concerns that tocilizumab may have worsened preexisting hyperbilirubinemia. Several patients also had transient elevations in serum transaminase values. Infections were the primary adverse events associated with tocilizumab administration. Four patients (67%) with aGVHD had either partial or complete responses apparent within the first 56 days of therapy. One patient with cGVHD had a significant response to therapy, whereas the second had stabilization of disease that allowed for a modest reduction in immune suppressive medications. These results indicate that tocilizumab has activity in the treatment of steroid refractory GVHD and warrants further investigation as a therapeutic option for this disorder.

Original languageEnglish (US)
Pages (from-to)1862-1868
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume17
Issue number12
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Graft vs Host Disease
Steroids
Therapeutics
Interleukin-6 Receptors
Skin
Hyperbilirubinemia
tocilizumab
Sclerosis
Transaminases
Gastrointestinal Tract
Adrenal Cortex Hormones
Stem Cells
Transplants
Antibodies
Infection
Serum
Population

Keywords

  • Graft-versus-host disease
  • Interleukin 6
  • Steroid refractory
  • Tocilizumab

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Drobyski, W. R., Pasquini, M., Kovatovic, K., Palmer, J., Douglas Rizzo, J., Saad, A., ... Hari, P. (2011). Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biology of Blood and Marrow Transplantation, 17(12), 1862-1868. https://doi.org/10.1016/j.bbmt.2011.07.001

Tocilizumab for the treatment of steroid refractory graft-versus-host disease. / Drobyski, William R.; Pasquini, Marcelo; Kovatovic, Kathy; Palmer, Jeanne; Douglas Rizzo, J.; Saad, Ayman; Saber, Wael; Hari, Parameswaran.

In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 12, 01.12.2011, p. 1862-1868.

Research output: Contribution to journalArticle

Drobyski, WR, Pasquini, M, Kovatovic, K, Palmer, J, Douglas Rizzo, J, Saad, A, Saber, W & Hari, P 2011, 'Tocilizumab for the treatment of steroid refractory graft-versus-host disease', Biology of Blood and Marrow Transplantation, vol. 17, no. 12, pp. 1862-1868. https://doi.org/10.1016/j.bbmt.2011.07.001
Drobyski, William R. ; Pasquini, Marcelo ; Kovatovic, Kathy ; Palmer, Jeanne ; Douglas Rizzo, J. ; Saad, Ayman ; Saber, Wael ; Hari, Parameswaran. / Tocilizumab for the treatment of steroid refractory graft-versus-host disease. In: Biology of Blood and Marrow Transplantation. 2011 ; Vol. 17, No. 12. pp. 1862-1868.
@article{a6083ac3663b4f1dbe9ca69cd255d6fb,
title = "Tocilizumab for the treatment of steroid refractory graft-versus-host disease",
abstract = "Corticosteroid refractory graft-versus-host disease (GVHD) is one of the major challenges in the management of allogeneic stem cell transplant recipients. Although numerous agents have been employed to treat this patient population, no standardized second-line therapy exists. In this study, we report our experience with the administration of tocilizumab, an anti-interleukin 6 receptor antibody, in the treatment of steroid refractory GVHD. Tocilizumab was administered to 8 patients with refractory acute (n = 6) or chronic GVHD (cGVHD) (n = 2) once every 3 to 4 weeks. The majority of patients with acute GVHD (aGVHD) had grade IV organ involvement of the skin or gastrointestinal tract, whereas both patients with cGVHD had long-standing severe skin sclerosis at the time of treatment. There were no allergic or infusion-related adverse events. Treatment was discontinued in one patient over concerns that tocilizumab may have worsened preexisting hyperbilirubinemia. Several patients also had transient elevations in serum transaminase values. Infections were the primary adverse events associated with tocilizumab administration. Four patients (67{\%}) with aGVHD had either partial or complete responses apparent within the first 56 days of therapy. One patient with cGVHD had a significant response to therapy, whereas the second had stabilization of disease that allowed for a modest reduction in immune suppressive medications. These results indicate that tocilizumab has activity in the treatment of steroid refractory GVHD and warrants further investigation as a therapeutic option for this disorder.",
keywords = "Graft-versus-host disease, Interleukin 6, Steroid refractory, Tocilizumab",
author = "Drobyski, {William R.} and Marcelo Pasquini and Kathy Kovatovic and Jeanne Palmer and {Douglas Rizzo}, J. and Ayman Saad and Wael Saber and Parameswaran Hari",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.bbmt.2011.07.001",
language = "English (US)",
volume = "17",
pages = "1862--1868",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Tocilizumab for the treatment of steroid refractory graft-versus-host disease

AU - Drobyski, William R.

AU - Pasquini, Marcelo

AU - Kovatovic, Kathy

AU - Palmer, Jeanne

AU - Douglas Rizzo, J.

AU - Saad, Ayman

AU - Saber, Wael

AU - Hari, Parameswaran

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Corticosteroid refractory graft-versus-host disease (GVHD) is one of the major challenges in the management of allogeneic stem cell transplant recipients. Although numerous agents have been employed to treat this patient population, no standardized second-line therapy exists. In this study, we report our experience with the administration of tocilizumab, an anti-interleukin 6 receptor antibody, in the treatment of steroid refractory GVHD. Tocilizumab was administered to 8 patients with refractory acute (n = 6) or chronic GVHD (cGVHD) (n = 2) once every 3 to 4 weeks. The majority of patients with acute GVHD (aGVHD) had grade IV organ involvement of the skin or gastrointestinal tract, whereas both patients with cGVHD had long-standing severe skin sclerosis at the time of treatment. There were no allergic or infusion-related adverse events. Treatment was discontinued in one patient over concerns that tocilizumab may have worsened preexisting hyperbilirubinemia. Several patients also had transient elevations in serum transaminase values. Infections were the primary adverse events associated with tocilizumab administration. Four patients (67%) with aGVHD had either partial or complete responses apparent within the first 56 days of therapy. One patient with cGVHD had a significant response to therapy, whereas the second had stabilization of disease that allowed for a modest reduction in immune suppressive medications. These results indicate that tocilizumab has activity in the treatment of steroid refractory GVHD and warrants further investigation as a therapeutic option for this disorder.

AB - Corticosteroid refractory graft-versus-host disease (GVHD) is one of the major challenges in the management of allogeneic stem cell transplant recipients. Although numerous agents have been employed to treat this patient population, no standardized second-line therapy exists. In this study, we report our experience with the administration of tocilizumab, an anti-interleukin 6 receptor antibody, in the treatment of steroid refractory GVHD. Tocilizumab was administered to 8 patients with refractory acute (n = 6) or chronic GVHD (cGVHD) (n = 2) once every 3 to 4 weeks. The majority of patients with acute GVHD (aGVHD) had grade IV organ involvement of the skin or gastrointestinal tract, whereas both patients with cGVHD had long-standing severe skin sclerosis at the time of treatment. There were no allergic or infusion-related adverse events. Treatment was discontinued in one patient over concerns that tocilizumab may have worsened preexisting hyperbilirubinemia. Several patients also had transient elevations in serum transaminase values. Infections were the primary adverse events associated with tocilizumab administration. Four patients (67%) with aGVHD had either partial or complete responses apparent within the first 56 days of therapy. One patient with cGVHD had a significant response to therapy, whereas the second had stabilization of disease that allowed for a modest reduction in immune suppressive medications. These results indicate that tocilizumab has activity in the treatment of steroid refractory GVHD and warrants further investigation as a therapeutic option for this disorder.

KW - Graft-versus-host disease

KW - Interleukin 6

KW - Steroid refractory

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=81255163590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81255163590&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.07.001

DO - 10.1016/j.bbmt.2011.07.001

M3 - Article

VL - 17

SP - 1862

EP - 1868

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -